Optimizing therapeutic approaches for HR+/HER2-advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
Juan Miguel Cejalvo Andújar, Francisco Ayala de la Peñ, Mireia Margeli Vila, Javier Pascual, Pablo Tolosa, Cristina Pages, Mónica Cuenca, Ángel Guerrero Zotano*
*Corresponding author for this work
- Clinic University Hospital of Valencia
- INCLIVA Health Research Institute
- Centro de Investigación Biomédica en Red de Cáncer
- Hospital Morales Meseguer
- Medical Oncology Department
- Institute of Biomedical Research in Málaga and Nanomedecin Platform (IBIMA Plataforma BIONAND)
- Hospital Universitario 12 de Octubre
- Pfizer Inc., New York
- Instituto Valenciano de Oncología (IVO)
Research output: Contribution to journal › Review article › Research › peer-review
5
Link opens in a new tab
Citations
(Scopus)